The nation of Zimbabwe has rejected a substantial US healthcare agreement valued at 367 million US dollars (£272m) over five years because of Washington's request for confidential information.
This move was revealed after a government memo from December was leaked, which showed President Emmerson Mnangagwa felt the agreement was "lopsided".
A government spokesman has since clarified that the US was demanding access to genetic material for research and profit but was not willing to guarantee the resulting advantages from future treatments.
"We are forced to start the challenging and unfortunate task of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged continued dialogue to find a agreement suitable to both sides so the nation's critical HIV treatment initiative can proceed.
Broader Background
This rejection follows a similar situation in Kenya, where a court suspended a related health funding agreement following concerns were filed about the security of citizens' health data.
Since returning to office last year, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump stated its spending was "wasteful" and his government was seeking direct bilateral agreements to enhance transparency and responsibility.
Based on statements, 16 African countries have to date agreed to similar agreements, representing more than $18.3bn in committed funds.
Specifics of the Declined Deal
The money for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation would have delivered extraordinary advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently on antiretroviral therapy through American-funded initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"Our nation was requested to share its genetic material and health information over an extended period, with no equivalent guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"Put simply, our nation would supply the basic resources for medical research with no assurance that the resulting innovations would be available to our population should a new pandemic emerge."
National Interest and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were disrupting structures previously set up via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to deal with future global health emergencies.
"This framework is intended to ensure that when a country contributes its samples, the benefits – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to create them."
The government's concerns regarding the US deal "must not be interpreted as opposition to America," he added.
"We encourage continued dialogue with our American counterparts on how subsequent co-operation could be structured in a way that respects the sovereignty and dignity of each country."
Medical Community Response
A leading public health body said it understood the official position, but recommended that talks need to persist considering a large portion of the nation's Aids initiatives relied on international support.
"In cases where technical issues exist, including those involving data governance or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," the group commented.
The halted deal emphasises the ongoing challenges between receiving crucial international aid and protecting a country's data in an ever more data-driven world.